Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Monthly Injectable BUP for MA Use Disorder (MURB) Trial
NCT05283304 · Madhukar H. Trivedi, MD · PHASE2 · terminated · last registry update 2025-03-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Side effects of medication” | – | Registry record, Madhukar H. Trivedi, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-16Phase 3 first posted: AgelessRx, Rapamycin + Naltrexone (NCT07475546)
- 2026-03-13Results posted on the registry: RAND, a drug against OPRM1 (NCT07072819)
- 2026-03-13Also stopped (suspended): Mauro Manconi, D-methadone (NCT04145674)
- 2026-03-09Also stopped (withdrawn): Universidad Europea de Canarias, pharmacological treatment by Opioids (NCT06240390)
- 2026-03-09Results posted on the registry: National Cancer Institute (NCI), E7 TCR cells + Aldesleukin (NCT02858310)
- 2026-03-09Also stopped (withdrawn): University of North Carolina, Chapel Hill, Morphine + Bupivacaine (NCT06784180)
- 2026-02-25Phase 3 first posted: Shenzhen Sciencare Medical Industries Co., Ltd., Naltrexone + placebo (NCT07433413)
- 2026-02-23Also stopped (withdrawn): Johns Hopkins University, Psilocybin (NCT06005662)
- 2026-02-20Results posted on the registry: University of Washington, a drug against OPRM1 (NCT06187064)
- 2026-02-18Also stopped (withdrawn): Rhode Island Hospital, Combined LAI Treatment: Cabenuva and Sublocade (NCT05991622)
- 2026-02-04Results posted on the registry: VA Office of Research and Development, a drug against OPRM1 (NCT05051644)
- 2026-02-03Also stopped (suspended): Friends Research Institute, Inc., Buprenorphine/Naloxone (NCT03616236)
- 2026-01-23Phase 3 first posted: VA Office of Research and Development, a drug against OPRM1 (NCT07361432)
- 2026-01-23Results posted on the registry: Hanoi Medical University, a drug against OPRM1 (NCT04706624)
- 2026-01-21Results posted on the registry: National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2026-01-21Also stopped (terminated): National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2026-01-15Also stopped (withdrawn): Massachusetts General Hospital, Buprenorphine/Naloxone (NCT04771689)
- 2026-01-14Results posted on the registry: Novo Nordisk A/S, Semaglutide + Orlistat (NCT05579249)
- 2026-01-07Results posted on the registry: University of Alabama at Birmingham, Placebos + Baclofen 5 mg (NCT04251819)
- 2026-01-07Also stopped (terminated): University of Alabama at Birmingham, Placebos + Baclofen 5 mg (NCT04251819)
- 2025-12-31Also stopped (withdrawn): Massachusetts General Hospital, Buprenorphine/naloxone (NCT04091009)
- 2025-12-23Results posted on the registry: Johns Hopkins University, Suvorexant (dual orexin receptor antagonist) + Placebo (NCT05546515)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-12-05Results posted on the registry: Henry Ford Health System, Methadone + Placebo (NCT02025855)
- 2025-12-05Also stopped (terminated): Henry Ford Health System, Methadone + Placebo (NCT02025855)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision